BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 8949983)

  • 21. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
    De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J
    Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
    du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
    Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
    Navari RM; Province WS; Perrine GM; Kilgore JR
    Cancer; 1993 Jul; 72(2):583-6. PubMed ID: 8319191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
    Robson S; McParlin C; Mossop H; Lie M; Fernandez-Garcia C; Howel D; Graham R; Ternent L; Steel A; Goudie N; Nadeem A; Phillipson J; Shehmar M; Simpson N; Tuffnell D; Campbell I; Williams R; O'Hara ME; McColl E; Nelson-Piercy C
    Health Technol Assess; 2021 Nov; 25(63):1-116. PubMed ID: 34782054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
    Meden H; Meissner O; Conrad A; Kuhn W
    Eur J Gynaecol Oncol; 1996; 17(2):114-22. PubMed ID: 8654467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
    Kenward H; Elliott J; Lee T; Pelligand L
    BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
    Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
    Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK
    Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of ondansetron plus dexamethasone in fractionated chemotherapy.
    Räth U; Upadhyaya BK; Arechavala E; Böckmann H; Dearnaley D; Droz JP; Fosså SD; Henriksson R; Aulitzky WE; Jones WG
    Oncology; 1993; 50(3):168-72. PubMed ID: 8459987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
    Jørgensen M; Victor MA
    Acta Oncol; 1996; 35(2):159-63. PubMed ID: 8639310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.